Correlation Between Visa and Franklin Genomic

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Visa and Franklin Genomic at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and Franklin Genomic into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Visa Class A and Franklin Genomic Advancements, you can compare the effects of market volatilities on Visa and Franklin Genomic and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of Franklin Genomic. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and Franklin Genomic.

Diversification Opportunities for Visa and Franklin Genomic

-0.68
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Visa and Franklin is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and Franklin Genomic Advancements in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Franklin Genomic Adv and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with Franklin Genomic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Franklin Genomic Adv has no effect on the direction of Visa i.e., Visa and Franklin Genomic go up and down completely randomly.

Pair Corralation between Visa and Franklin Genomic

Taking into account the 90-day investment horizon Visa Class A is expected to generate 0.79 times more return on investment than Franklin Genomic. However, Visa Class A is 1.26 times less risky than Franklin Genomic. It trades about 0.4 of its potential returns per unit of risk. Franklin Genomic Advancements is currently generating about 0.0 per unit of risk. If you would invest  28,134  in Visa Class A on August 30, 2024 and sell it today you would earn a total of  3,336  from holding Visa Class A or generate 11.86% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Visa Class A  vs.  Franklin Genomic Advancements

 Performance 
       Timeline  
Visa Class A 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Visa Class A are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Visa showed solid returns over the last few months and may actually be approaching a breakup point.
Franklin Genomic Adv 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Franklin Genomic Advancements has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Etf's essential indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the ETF investors.

Visa and Franklin Genomic Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Visa and Franklin Genomic

The main advantage of trading using opposite Visa and Franklin Genomic positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, Franklin Genomic can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Franklin Genomic will offset losses from the drop in Franklin Genomic's long position.
The idea behind Visa Class A and Franklin Genomic Advancements pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Complementary Tools

Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world